

## FORMA THERAPEUTICS AND CANCER RESEARCH TECHNOLOGY TO DISCOVER CANCER DRUGS TARGETING DEUBIQUITINATING ENZYMES (DUBS)

---

July 9, 2013

*Unique Business Model Implements Independent, Wholly Owned Asset Discovery and Development Company (ADDCo) Subsidiaries for Target Programs*

**WATERTOWN, Mass. and LONDON, July 9, 2013** – FORMA Therapeutics and Cancer Research Technology, Ltd. (CRT), the commercialization company of Cancer Research UK (CRUK), announced today a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes (DUBs). Under this agreement, FORMA will pair its ultra-efficient drug discovery capabilities with CRT’s expertise in translating academic discoveries through its Discovery Laboratories (CRT-DL) and the exclusive world-class academic network of CRUK Principal Investigators.

“This initiative with CRT and CRUK has the potential to significantly accelerate our understanding of the relevant biological applications of DUBs, a key class of enzymes involved in regulating protein homeostasis,” said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. “We are particularly looking forward to working closely in this initiative with CRT’s Discovery Laboratories and a group of preeminent investigators, who bring critical insights in this area of important biology and have proven track records in basic and translational research.”

Keith Blundy, CEO of Cancer Research Technology stated, “Cancer Research UK’s breadth of research combined with CRT-DL’s drug discovery capabilities are a unique platform that has secured the FORMA relationship and will contribute to bringing breakthrough cancer therapeutics to patients.”

Protein ubiquitination is involved in many cellular processes and its regulation is controlled in part by DUBs. Ubiquitin “tags” proteins for degradation, and DUBs remove this tag, providing a tool for manipulating protein levels (protein homeostasis) in a cell. Ubiquitin biology is therefore complex and important to a broad range of human diseases. FORMA and CRT-DL will leverage their combined strengths to explore the protease enzymes that regulate ubiquitin-dependent pathways implicated in cancer.